ライフサイエンスコーパス: fungal infection

1 f compounds that act specifically to prevent fungal infection.

2 ssion in wood compared to bark tissues after fungal infection.

3 bute to the de novo biosynthesis of JA after fungal infection.

4 NK1 may be a therapeutic target for treating fungal infection.

5 ted outcome of CLR ligation in bacterial and fungal infection.

6 xity regulating the fly response to systemic fungal infection.

7 the host cuticle during the early stages of fungal infection.

8 y an unacceptably high risk of postoperative fungal infection.

9 gatively regulate host immune responses to a fungal infection.

10 on of the insect reproductive tissues during fungal infection.

11 in improving the prognosis for patients with fungal infection.

12 l, we investigated the link between ESCC and fungal infection.

13 000Gy promoted browning of the calyx end and fungal infection.

14 es consultation for an invasive bacterial or fungal infection.

15 structures for in situ, real-time imaging of fungal infection.

16 nnial indoor allergens and asthma related to fungal infection.

17 egs) using a model of Histoplasma capsulatum fungal infection.

18 ell as change to rice innate immunity during fungal infection.

19 vitro and in vivo and promotes Tregs during fungal infection.

20 l-arabitol or creatinine, is indicative of a fungal infection.

21 . oryzae, at multiple time points during the fungal infection.

22 patients, often without documented invasive fungal infection.

23 hat are likely related to localized areas of fungal infection.

24 nt inflammasome responses to a DNA virus and fungal infection.

25 ediates the activation of Syk in response to fungal infection.

26 ficient mice had increased susceptibility to fungal infection.

27 e prophylaxis group developed a breakthrough fungal infection.

28 imaging for patients with suspected invasive fungal infection.

29 ved in the proteins expressed in response to fungal infection.

30 g conditions to identify possible markers of fungal infection.

31 e of all BAL fluid samples were negative for fungal infection.

32 ize cell proliferation occurs independent of fungal infection.

33 rmin inhibited the innate immune response to fungal infection.

34 Mucormycosis is rare, life-threatening fungal infection.

35 only transcripts of AGO4 were elicited after fungal infection.

36 suppressor of host defense against systemic fungal infection.

37 y and efficacy in a murine model of invasive fungal infection.

38 tients with detrimental immunity to invasive fungal infection.

39 y in zebrafish and murine models of systemic fungal infection.

40 s available to treat drug-resistant invasive fungal infections.

41 ergillosis, mucormycosis, and other invasive fungal infections.

42 s in the diagnosis and treatment of invasive fungal infections.

43 urses were not consistent with true invasive fungal infections.

44 nity may render these patients vulnerable to fungal infections.

45 linical management of patients with invasive fungal infections.

46 sential to maintain adequate protection from fungal infections.

47 atients with opportunistic, life-threatening fungal infections.

48 is to prevent life-threatening bacterial and fungal infections.

49 e innate immune system to recognize systemic fungal infections.

50 r, and about a billion people have cutaneous fungal infections.

51 treatment of disseminated, life-threatening fungal infections.

52 for developing novel strategies for treating fungal infections.

53 f Spt14 inhibitors for treatment of invasive fungal infections.

54 o prevent and mitigate serious bacterial and fungal infections.

55 ve drugs have a higher incidence of invasive fungal infections.

56 Colony expansion is an essential feature of fungal infections.

57 loping desperately needed therapies to treat fungal infections.

58 ole currently used in the treatment of human fungal infections.

59 d to treat humans afflicted with filamentous fungal infections.

60 ould serve as a portal of entry for invasive fungal infections.

61 data are lacking from patients with invasive fungal infections.

62 d host niches such as in the brain to combat fungal infections.

63 ogenesis and signaling during hemibiotrophic fungal infections.

64 han those in in serum in noncryptococcal CNS fungal infections.

65 therapies for both autoimmune conditions and fungal infections.

66 dical ailments but have yet to be applied to fungal infections.

67 which provide protection from bacterial and fungal infections.

68 e fungal pathogenicity and host responses to fungal infections.

69 roduction of substances that promote chronic fungal infections.

70 ved prognosis and disease management against fungal infections.

71 nutrient restriction resulting in secondary fungal infections.

72 ew therapeutic strategies to combat invasive fungal infections.

73 treatment of hypercholesteremia, cancer, and fungal infections.

74 with an increased risk of mycobacterial and fungal infections.

75 lay an essential role in the pathogenesis of fungal infections.

76 dysfunction have increased susceptibility to fungal infections.

77 tream is a critical step leading to invasive fungal infections.

78 1,3-glucan, is vital to host defense against fungal infections.

79 tial link to cause disseminated and invasive fungal infections.

80 s none), sepsis (2.94 [2.70-3.21]), invasive fungal infection (1.20 [1.02-1.42]), and pneumonia (1.13

81 s none), sepsis (4.61 [4.34-4.89]), invasive fungal infection (1.24 [1.11-1.39]), and pneumonia (1.73

82 f lower bacterial (32% vs 46%; P < 0.05) and fungal infection (2% vs 11%; P < 0.05).

83 3 or worse adverse events were bacterial or fungal infections (47 [20%] of 232 in the intravenous PE

84 Fungal infections affected 28.1% and were more common in

85 gnificant difference in bacterial, viral, or fungal infections after transplant.

86 S. aureus, P. aeruginosa, C. difficile, and fungal infections all had high prevalence in specific ch

87 In addition, CRS with fungal and non-fungal infections also demonstrated a significant associ

88 As a rapid response to fungal infection an overexpression of phosphatidic acids

89 cell fates in inflammatory contexts of acute fungal infection and chronic autoimmunity.

90 entral tolerance, are susceptible to chronic fungal infection and esophageal squamous cell carcinoma

91 nometabolic regulation of macrophages during fungal infection and highlight the metabolic repurposing

92 Autoreactive CD4 T cells permit fungal infection and incite tissue injury and inflammati

93 tLYK3 is strongly repressed by elicitors and fungal infection and is induced by the hormone abscisic

94 Direct microscopic examination showed fungal infection and results of mycological culture were

95 re evaluated in the corneas of the mice with fungal infection and the control corneas by real-time PC

96 ether this pathway contributes to persistent fungal infection and to determine whether anti-PD-1 Ab t

97 Fungal infection and wasp parasitization induced express

98 Softening, fungal infection and weight loss increased during cold s

99 Six patients (5%) developed invasive fungal infections and 5 patients (4%) had life-threateni

100 by recurrent life-threatening bacterial and fungal infections and aberrant inflammation.

101 D), characterized by recurrent bacterial and fungal infections and aberrant inflammation.

102 alidated tool for the clinical management of fungal infections and for epidemiological studies.

103 d for patients at risk for mycobacterial and fungal infections and for infection with B. pseudomallei

104 ellular defense in response to bacterial and fungal infections and rely on granular proteins to kill

105 the development of new strategies to manage fungal infections and to modulate the potency of current

106 ferences in sex, collection timing, bacteria/fungal infection, and corticosteroid treatment limit int

107 ral tolerance, autoreactive T cells, chronic fungal infection, and ESCCs expressing specific human ES

108 diverse as solid tumors, drug resistance in fungal infection, and normal development.

109 asured survival and pathogen load after live fungal infection, and we characterized the aphid immune

110 d cell death that occur during opportunistic fungal infections, and explore how cell death pathways m

111 a albicans is an important cause of systemic fungal infections, and rapid diagnostics for identifying

112 Opportunistic fungal infections are a leading cause of death among imm

113 Fungal infections are a major challenge to human health

114 Fungal infections are a major contributor to infectious

115 Invasive fungal infections are an important infection concern for

116 Fungal infections are an increasing clinical problem.

117 Systemic fungal infections are an increasingly prevalent health p

118 Fungal infections are being caused by a broadening spect

119 Background: Fungal infections are of increasing incidence and import

120 Fungal infections are of major relevance due to the incr

121 Fungal infections are on the rise due to new medical pro

122 Fungal infections are responsible for millions of human

123 an increased susceptibility to bacterial and fungal infections as a result of impaired leukocyte recr

124 Interestingly, age may also affect skin fungal infections as certain dermatophytoses (i.e., tine

125 n also be induced by bacterial, protozoal or fungal infections as well as a wide variety of toxic sub

126 of augmented immunity against bacterial and fungal infection, as well as assessment of hematopoietic

127 ased susceptibility to bacterial, viral, and fungal infections, as well as autoimmunity.

128 be taken for patients with large ulcers and fungal infections, as well as elderly patients with como

129 es occupied by Elysia, apparently to prevent fungal infection associated with Elysia feeding.

130 roles in host defense against bacterial and fungal infections at different epithelial sites, but its

131 ing C12 or C14 with azoles to treat invasive fungal infections at lower administration doses or with

132 ngness-to-pay threshold (WTP) of $20 000 per fungal infection averted.

133 etrospective review of breakthrough invasive fungal infections (bIFIs) among adult hematologic malign

134 ognostic aid of central nervous system (CNS) fungal infection, but its relationship to serum values h

135 previously implicated in protection against fungal infection, but their roles in antifungal immunity

136 eding depression related to stress caused by fungal infection, but which was not associated with dens

137 ential for the defense against bacterial and fungal infections, but also contributes to tissue damage

138 first line of defense against bacterial and fungal infections, but they are also important effectors

139 Although the fungal infection by O. novo-ulmi primarily takes places

140 0.14) but significantly decreased secondary fungal infections by 50% (risk ratio, 0.49; 95% CI, 0.35

141 human neutrophils to the protection against fungal infections by Aspergillus fumigatus is essential

142 Among 263 fungal infections, Candida spp (60%) prevailed as digest

143 Fungal infection carried a higher risk of mortality than

144 Invasive fungal infections cause 1.6 million deaths annually, pri

145 ection breaks down, superficial and invasive fungal infections cause diseases that range from irritat

146 Fungal infections cause morbidity worldwide and are asso

147 Invasive fungal infections cause significant morbidity and mortal

148 Chromoblastomycosis (CBM) is a chronic fungal infection caused mainly by the melanized fungi Fo

149 osensors are suitable for early diagnosis of fungal infections caused by Candida sp. yeasts.

150 Fungal infections caused by Candida spp. represent an em

151 It is estimated that fungal infections, caused most commonly by Candida albic

152 Finally, the fungal infection causes a strong imbalance in plant suga

153 g is associated with lower rates of invasive fungal infections compared with placebo or no interventi

154 ic, and therapeutic interventions, resistant fungal infections continue to cause significant morbidit

155 Serious fungal infections continue to devastate people living wi

156 Opportunistic fungal infections continue to take an unacceptably heavy

157 of patients at risk for developing invasive fungal infections continues to increase.

158 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and Mycoses Study Gr

159 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institu

160 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institu

161 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Ins

162 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Ins

163 or Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group criteria, and assess

164 or Research and Treatment of Cancer Invasive Fungal Infections Cooperative Group/Mycoses Study Group

165 The outcome of fungal infections depends on interactions with innate im

166 The results indicate that fungal infection down-regulated FOXA2 expression in airw

167 e host response regulating specific types of fungal infections (e.g., mucocutaneous versus systemic).

168 Eumycetoma, a chronic fungal infection endemic in India, Indonesia, and parts

169 nt host-pathogen interaction contributing to fungal infection establishment patterns.

170 Therefore, autoreactive T cells and chronic fungal infection, fostered by inflammation and epithelia

171 gin, compared with placebo, did not increase fungal infection-free survival at day 28.

172 an increase in the proportion of filamentary fungal infections from the pre-2007 data.

173 ll lung cancer (adenocarcinomas) from benign fungal infection (granulomas) on 120 non-contrast CT stu

174 The incidence of systemic fungal infections has decreased in people with HIV in hi

175 wing need for newer agents to treat systemic fungal infections has escalated due to increasing resist

176 antifungal therapy, initiated for suspected fungal infection, has not been shown to improve outcome.

177 Invasive fungal infections have a devastating impact on human hea

178 Invasive fungal infections have a high rate of morbidity and mort

179 Available treatments for invasive fungal infections have limitations, including toxicity a

180 17), which is important in controlling other fungal infections, have not been clearly defined.

181 the increasing incidence of postkeratoplasty fungal infection, however, the addition of amphotericin

182 Invasive fungal infection (IFI) following liver transplant is ass

183 ts with predefined risk factors for invasive fungal infection (IFI), a prospective phase II noncompar

184 hether empirical micafungin reduces invasive fungal infection (IFI)-free survival at day 28.

185 ost common pathogen responsible for invasive fungal infection (IFI).

186 Prompt diagnosis of invasive fungal infections (IFI) remains a challenge.

187 VZV], blood stream infection [BSI], invasive fungal infection [IFI]) or death occurring after one mon

188 Combat trauma wounds with invasive fungal infections (IFIs) are often polymicrobial with fu

189 e outbreaks have drawn attention to invasive fungal infections (IFIs) as an increasingly important pu

190 Appropriate diagnosis of invasive fungal infections (IFIs) is critical due to the high rat

191 nsplant recipients commonly develop invasive fungal infections (IFIs), but the most effective strateg

192 r transplant recipients at risk for invasive fungal infections (IFIs), GM and BG were assessed in 199

193 icafungin decreased the rate of new invasive fungal infection in 4 of 128 patients (3%) in the micafu

194 dial and appressorium formation, to restrict fungal infection in chilli and tomato fruits.

195 d before definitive diagnosis of an invasive fungal infection in critically ill patients without neut

196 me cases, reducing the incidence of invasive fungal infection in critically ill patients.

197 hip between autoreactive T cells and chronic fungal infection in ESCC development remains unclear.

198 gillosis (IA) is a life-threatening systemic fungal infection in immunocompromised individuals that i

199 Diagnosis of fungal infection in lung parenchyma is relatively diffic

200 oduction and increased mortality in systemic fungal infection in mice.

201 nfection in 64 patients (47.8%), an isolated fungal infection in nine patients (6.7%), and a coinfect

202 ves accumulated significantly at the site of fungal infection in the lower epidermis.

203 tive period or had a history of bacterial or fungal infection in the preceding 30 days.

204 cant promise for the rapid identification of fungal infection in trauma-related injuries, leading to

205 that cause the majority of life-threatening fungal infections in humans.

206 ermatophytes cause superficial and cutaneous fungal infections in immunocompetent hosts and invasive

207 ococcus species are associated with invasive fungal infections in immunosuppressed individuals.

208 iciencies responsible for the higher risk of fungal infections in patients with immunosuppressive dis

209 use of enzymes as biocontrol agents against fungal infections in post-harvest fruits and vegetables.

210 monas aeruginosa, Clostridium difficile, and fungal infections) in pediatric sepsis patients in a con

211 ty-one recipients (21.6%) developed invasive fungal infections, including 29 patients (8.8%) with IPA

212 recurrent fungal disease, and resistance to fungal infection is a complex trait.

213 Invasive fungal infection is a serious health threat with high mo

214 nvasive pulmonary aspergillosis in which the fungal infection is entirely or predominantly confined t

215 identification of the agents of subcutaneous fungal infection is essential to guide appropriate antif

216 Fungal infection is highly associated with ESCCs in non-

217 rice transcriptome and its variation during fungal infection is necessary to understand the complex

218 ministered prior to diagnosis of an invasive fungal infection is not associated with either higher or

219 dida, Cryptococcus, and Aspergillus Treating fungal infections is challenging, in part due to the eme

220 utility of molecular diagnostics in invasive fungal infections is discussed.

221 The proportion of postkeratoplasty fungal infections is rising steadily.

222 dida invasion, an important step in limiting fungal infection, is significantly reduced in mBD1-defic

223 Human fungal infections may fail to respond to contemporary an

224 Neonate susceptibility to fungal infections may not be due to an inability of thei

225 EntV(68) is protective in three fungal infection models at nanomolar or lower concentrat

226 Fungal infections modulate the lung immune response, ind

227 , all tissue-based neutrophilic responses to fungal infections necessitate contact with the extracell

228 All serious fungal infections need appropriate antifungal therapy fo

229 neumonia is a life-threatening opportunistic fungal infection observed in individuals with severe imm

230 Invasive aspergillosis and other fungal infections occur in immunocompromised individuals

231 elicited at a distance from the trunk where fungal infections occur.

232 k factors were independently associated with fungal infections (odds ratio for AIDS and hematological

233 oxins can contaminate poultry production via fungal infection of feeds.

234 Nosemosis is a fungal infection of honey bees caused by either Nosema a

235 metagenomics and network inference show that fungal infection of plant roots enriched for Chitinophag

236 Lethal systemic fungal infections of Candida species are increasingly co

237 Isolated invasive fungal infections of unclear cellular basis are associat

238 uppressed patients at high risk for invasive fungal infections often have prolonged or repeated expos

239 However, the effects of fungal infection on host thermal limits have not been ex

240 We tested for effects of fungal infection on host thermal tolerance in a model sy

241 confidence interval [CI], 1.1-1.8), invasive fungal infection (OR, 1.3; 95% CI, 1.1-1.5), and donor a

242 Systemic fungal infections pose a serious clinical problem.

243 CEA were the incidences of postkeratoplasty fungal infections, potential increases in graft failures

244 d year crop yield in the context of take-all fungal infection presented the opportunity to examine so

245 natural epidemics and tracked edible algae, fungal infection prevalence, body size, fecundity and de

246 ctions with methicillin-resistant S. aureus, fungal infections, Pseudomonas infections, and C. diffic

247 e mortality and may have decreased secondary fungal infection rates.

248 umigatus, and is a leading cause of invasive fungal infection-related mortality and morbidity in pati

249 istic fungal pathogen and a leading cause of fungal-infection-related fatalities, especially in immun

250 es.Conclusions: Rapid, accurate diagnosis of fungal infections relies on appropriate application of l

251 Bacterial and fungal infections remain a major clinical challenge.

252 Fungal infections remain a major determinant of survival

253 Fungal infections remain a threat due to the lack of bro

254 Invasive fungal infection remains a serious postoperative complic

255 ole in plant immunity against hemibiotrophic fungal infection remains poorly understood.

256 ct detrimental inflammatory responses during fungal infection remains unknown.

257 al spores by air sampling for acquisition of fungal infections remains to be determined.

258 Systemic fungal infections represent an important public health c

259 Nosocomial fungal infections require a robust scientific response t

260 ing protein 1 (ZBP1) as the apical sensor of fungal infection responsible for activating the inflamma

261 the epidemiology and risk factors for common fungal infections seen in lung transplant recipients, ev

262 The kidney that serves as the major site of fungal infection showed an initial rise in Cu, followed

263 The fungal infection significantly reduced lipase activity a

264 dstream infections (six [16%]), and invasive fungal infections (six [16%]).

265 needed to accurately assess the risk of this fungal infection, specifically in patients on immunomodu

266 Fungal infection stimulates the canonical C-type lectin

267 Impairing the function of fungal infection structures therefore provides a potenti

268 Azoles are antifungal drugs used to treat fungal infections such as candidiasis in humans.

269 Key secondary end points included new proven fungal infections, survival at day 28 and day 90, organ

270 ncerns about the burden of the bacterial and fungal infection syndromes related to injection drug use

271 sequences of an immune response to pulmonary fungal infection that can ultimately affect disease.

272 Eumycetoma is a debilitating, chronic, fungal infection that is endemic in India, Indonesia, an

273 Cryptococcal meningoencephalitis is a fungal infection that predominantly affects immunocompro

274 nsible for cryptococcosis, a deadly invasive fungal infection that represents around 220,000 cases pe

275 tions unique to AFS and the complex field of fungal infections that require specific recommendations.

276 iosynthesis were actively transcribed during fungal infection, there was a significant time-dependent

277 esence of neutrophils in acute bacterial and fungal infections, these findings will have implications

278 of patients with cryptococcosis or dimorphic fungal infections treated with ISAV.

279 orescences of maize under local and systemic fungal infection treatments, respectively.

280 Systemic fungal infections trigger marked immune-regulatory distu

281 Together, these studies demonstrate that fungal infection triggers marked fluctuations in host Cu

282 obesity: HR = 5.19, 95% CI: 3.38, 7.95), and fungal infections (underweight: HR = 3.19, 95% CI: 1.53,

283 ults and the development of postkeratoplasty fungal infection using corresponding corneal tissue.

284 icosteroid use, right heart catheterization, fungal infection, vasopressor use, and a mean arterial p

285 tality of construction/renovation-associated fungal infection was approximately 50%.

286 Fungal infection was detected in 176 (74%) and Acanthamo

287 and TNFalpha in the corneas of the mice with fungal infection was determined by ELISA.

288 of L-ficolin in BAL fluid from patients with fungal infection was significantly higher than that for

289 elucidate the role of Notch signaling during fungal infections, we infected mice expressing the pan-N

290 peutic indices for the treatment of invasive fungal infections, we initiated a program to design and

291 Fruit parameters in terms of firmness, fungal infection, weight loss, total phenol concentratio

292 d with lower rates of mortality and invasive fungal infections when administered before definitive di

293 demonstrating that CHI3L1 is induced during fungal infection, where it acts as an immunomodulator to

294 arding significant risk factors for invasive fungal infection, which has limited the development and

295 atively low, but growing, number of systemic fungal infections, which creates significant hurdles in

296 IVCM sensitivity was higher in patients with fungal infections who had positive culture or longer dur

297 is new triazole in the treatment of invasive fungal infections will be better defined.

298 redisposed to mucormycosis, an angioinvasive fungal infection with high mortality.

299 idiasis is one of the most common nosocomial fungal infections worldwide.

300 Candida albicans is the leading cause of fungal infections; yet, complex genetic interaction anal